28 - 30 June, 2011, America Square Conference Centre, London
Register by 3rd june 2011 and receive up to £400 off!
Download the Brochure
Visit the Media Centre for complimentary industry related content!
Become a Pharma IQ Member and receive our weekly newsletter!
Learn more about sponsor & exhibit opportunities
Mark Your Calendar
Tell a Colleague
Download the brochure
Current estimates indicate that 40% of drugs on the market place and 90% of APIs in development are poorly soluble.
The 7th Annual Improving Solubility conference will investigate classic and novel drug delivery solutions utilised to improve bioavailability, increase uptake and expedite time-to-market of new chemical entities as well as reformulated compounds in the development pipeline.
After receiving over 350 individuals from 200 organisations over the last 6 years, this year’s Improving Solubility Summit really is the perfect opportunity for you to uncover the very latest techniques, technologies, solutions and best practice methods for you to implement into your drug development strategy
Dr. David Elder, Externalization Director at GlaxoSmithKline talks exclusively about GSK’s recent work on identifying drugable, trackable targets to improving solubility of biopharmaceutical compounds.
To see the complete interview, which includes Dr. Elder’s perspective across the industry, including externalisation, stability, amorphous forms and genotoxic and carcinogenic impurities, click here
To find out more about the event, navigate using the following options:
"Very helpful and good insights into the formulation problems and how to overcome them" Marco Gil Hovione Farmaciencia
"Interesting and exciting speakers willing to create discussion and to elaborate the presented themes. It was extremely valuable." Isabel Sequeira, Hovione Farmaciencia
"Good balance between technical presentations & practical ones"Nuria Cubel Sune, Lab Esteve
"It was very valuable to have an overview about techniques which can be used and which basics are needed for this. It showed me that other pharmaceutical companies are faced with the same problems and to exchange on this" Susanne Tollar, Solvay Pharmaceuticals
[ Register Now ]